摘要:目的:了解甘精胰岛素联合二甲双胍治疗对口服降糖药血糖控制不理想的2型糖尿病患者的疗效和安全性。方法:对30例口服降糖药血糖控制不理想的2型糖尿病患者给与甘精胰岛素联合二甲双胍治疗,共12周。治疗前后测身高、体重、空腹血糖(FPG)、餐后2小时血糖(PPG)以及糖化血红蛋白(HbA1c)水平。了解治疗期间低血糖发生情况。结果:治疗后的FPG、PPG以及HbA1c水平明显下降,分别下降了303mmol/L、510mmol/L和198%,差异有统计学意义(Plt;005)。治疗后5330%的患者HbA1c水平lt;70%。治疗前HbA1c水平≥70%lt;90%的患者,治疗后706%的患者HbA1c水平lt;70%,治疗前HbA1c水平≥90%的患者,治疗后307%的患者HbA1c水平lt;70%,两者的HbA1c达标率有明显差异(Plt;005)。治疗前后体重及BMI无明显差异(Pgt;005)。30例患者中仅发生两次轻微低血糖。结论:甘精胰岛素联合二甲双胍治疗对口服降糖药治疗血糖控制不理想的2型糖尿病患者是安全有效的,尤其是对HbA1c水平lt;90%的患者,血糖控制更好,达标率更高。
目的:探讨活体右半肝移植供体术后并发症及其处理。方法:回顾性分析了我院肝移植中心的120例活体肝移植供体术后并发症发生的类型和临床处理方法。结果:120例活体肝移植供体术后都出现肝功能实验室指标的短期变化,其中114例术后1周内恢复正常;6例恢复时间大于1周。术后并发症总发生率9.16%,其中严重并发症发生率4.16%,轻微并发症发生率5.00%。所有术后并发症得到及时的发现和处理,恢复良好。结论:经过严密的术前检查和评估、充分的术前准备、细致的术中操作和全面的术后监护与治疗,活体右半肝移植供体的手术安全性较高,近期预后较好。
摘要:目的:探讨胺碘酮治疗充血性心力衰竭(CHF)心房颤动伴快速心室率的临床疗效。方法: 将106例各种原因所致的房颤伴快速心室率的CHF患者按入院顺序随机分为治疗组及对照组。两组抗CHF基础治疗相同,治疗组加用静脉负荷量胺碘酮150 mg后,再以1 000μg/min静脉点滴维持6小时,500 μg/min静滴18小时。同时口服胺碘酮0.2,3次/d,1周;再0.2,2次/d,1周以后以0.2,1次/d 至观察终点,随诊为12个月。 结果: 治疗组53例使用胺碘酮治疗可显著增加抗心律失常有效性,改善左室射血分数,减少心力衰竭再住院率,42例患者转复为室性心律。 结论: 静脉及口服胺碘酮同时应用治疗充血性心力衰竭房颤是有效和安全的。Abstract: Objective: To explore the effect and safety of amiodarone in the treatment of atrial fibrillation with congestive heart failure. Methods:One hundred and six patients of AF with CHF caused by a variety of reasons were randomly divided into treatment group and control group according to hospitalized order.The two groups were treated with the same antiCHF therapy,the treatment group was treated with loaded intravenous amiodarone 150 mg;and then dripped to 1 000 μg/min for 6 hours, dripped to 500 μg/min for 18 hours. United with oral amiodarone by amiodarone tablets with 0.2 g,3 time/day a week,further 0.2 g,2 times/day a week,later 0.2 g,1 times/day to the end.The end of followup time was 12 months. Results:In treatment group,53 cases with amiodarone therapy can significantly increase the effectives of antiarrhythmic, improve the rate and heart failure rehospitalization.42/53 patients reversed to sinus rhythm. Conclusion:The results showed it is effective and safe united with intravenous amiodarone and oral amiodarone in treatment of atrial fibrillation with organic heart disease.